Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy
Authors:
Open Access
- 3 April 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-9
Abstract
Liquid biopsies, which analyze circulating tumor cells or cell-free circulating tumor DNA (ctDNA) from blood, have emerged as promising cancer detection and monitoring tools. Specifically, human papillomavirus (HPV) cell-free (cf) DNA is gaining recognition as a prognostic marker in high-risk HPV-related cancers. However, detecting circulating markers for cervical cancer (CC) requires highly sensitive techniques to quantify circulating HPV DNA. This study aimed to evaluate the use of droplet digital PCR (ddPCR), a highly sensitive technique, for detecting and quantifying circulating HPV DNA in cervical cancer patients, both at baseline (before chemo- or radiotherapy) and during follow-up, to assess its utility as a prognostic marker. Blood samples were collected from 60 cervical cancer patients (Stages I–IV) at AIIMS, New Delhi, at baseline and three months post-treatment. Samples from 10 healthy controls were also included. Plasma was separated and stored at − 80 °C, and cfDNA was extracted from 1 ml of plasma. The presence of high-risk HPV types, HPV16 and HPV18, in cfDNA from 35 patients was assessed using ddPCR. The median concentration of cfDNA in cervical cancer patients was 9.35 ng/µL at baseline, which decreased to 7 ng/µL after three months of treatment. In healthy controls, the median cfDNA concentration was 6.95 ng/µL. ddPCR screening showed that detection rates for HPV18 and HPV16 detection were 45.71% and 82.86%, respectively. A significant correlation was observed between cf HPV16 DNA levels and tumor size, suggesting its potential as biomarker for disease burden.Keywords
Funding Information
- Sidra Medicine (SDR400190, SDR400189)
- All-India Institute of Medical Sciences (A825)
This publication has 20 references indexed in Scilit:
- Detection of Circulating HPV16 DNA as a Biomarker for Cervical Cancer by a Bead-Based HPV Genotyping AssayMicrobiology Spectrum, 2022
- Residual ctDNA after treatment predicts early relapse in patients with early-stage non-small cell lung cancerAnnals of Oncology, 2022
- Circulating HPV DNA as a Marker for Early Detection of Relapse in Patients with Cervical CancerClinical Cancer Research, 2021
- Rapid and ultrasensitive detection of circulating human papillomavirus E7 cell-free DNA as a cervical cancer biomarkerExperimental Biology and Medicine, 2020
- Diagnostic Accuracy of Cervical Pap Smear and Colposcopy in Detecting Premalignant and Malignant Lesions of CervixIndian Journal of Surgical Oncology, 2020
- Risk of recurrence, prognosis, and follow‐up for Danish women with cervical cancer in 2005‐2013: A national cohort studyCancer, 2017
- Circulating human papillomavirus DNA detected using droplet digital PCR in the serum of patients diagnosed with early stage human papillomavirus‐associated invasive carcinomaThe Journal of Pathology: Clinical Research, 2016
- Evaluation of a Droplet Digital Polymerase Chain Reaction Format for DNA Copy Number QuantificationAnalytical Chemistry, 2011
- High-Throughput Droplet Digital PCR System for Absolute Quantitation of DNA Copy NumberAnalytical Chemistry, 2011
- Overview of the European and North American studies on HPV testing in primary cervical cancer screeningInternational Journal of Cancer, 2006